{
    "clinical_study": {
        "@rank": "149492", 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect safety data on ALFALASTIN\u00ae infusions performed at\n      home or in out-of hospital locations."
        }, 
        "brief_title": "Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Alpha 1-Antitrypsin Deficiency", 
        "condition_browse": {
            "mesh_term": "Alpha 1-Antitrypsin Deficiency"
        }, 
        "detailed_description": {
            "textblock": "Non interventional, observational, longitudinal, prospective, multicenter, non comparative\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Participation Criteria:\n\n          -  Patients above 18 y.o,\n\n          -  suffering from severe forms of primary alpha-1 antitrypsin deficiency, phenotype PiZZ\n             or PiSZ with pulmonary emphysema,\n\n          -  currently treated as per routine practice, once a week, by ALFALASTIN\u00ae at home or in\n             out-of-hospital location\n\n          -  and having signed informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients above 18 y.o, suffering from severe forms of primary alpha-1 antitrypsin\n        deficiency, phenotype PiZZ or PiSZ with pulmonary emphysema, currently treated , once a\n        week, as per routine practice by ALFALASTIN\u00ae at home or in out-of-hospital location."
            }
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676688", 
            "org_study_id": "AlfaDom"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "alpha-1 antitrypsin", 
            "deficiency", 
            "Alfalastin", 
            "safety"
        ], 
        "lastchanged_date": "November 8, 2012", 
        "number_of_groups": "1", 
        "official_title": "Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.", 
        "overall_official": [
            {
                "affiliation": "Pneumology - CHU Rouen, France", 
                "last_name": "Cuvelier Antoine, Prof.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Pneumology - CHU Lyon, France", 
                "last_name": "Mornex Jean-Fran\u00e7ois, Prof", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Pneumology - H\u00f4pital Bichat Paris, France", 
                "last_name": "Thabut Gabriel, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "France: French Data Protection Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Conseil National de l'Ordre des M\u00e9decins"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}